LINC01607 promotes hepatocellular carcinoma progression and ferroptosis-associated therapy resistance with functional involvement of the p62–Keap1–Nrf2 pathway

Cancer Drug Resistance · Published 2026-07-17 · DOI 10.20517/cdr.2026.02

Free full text

Authors (8)

Yuxin Zhang, Weiqi Xu, Fangling Cheng, Jinghan Zhu, Yuanxiang Lu, Guangzhen Cai, Jiang Li, Yujie Zhang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Zhang, Y., Xu, W., Cheng, F., et al. (2026). LINC01607 promotes hepatocellular carcinoma progression and ferroptosis-associated therapy resistance with functional involvement of the p62–Keap1–Nrf2 pathway. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2026.02

Related articles

• KLF5 promotes tumor proliferation and oxaliplatin resistance via chromatin remodeling in KRAS-mutated colorectal cancer · Cancer Drug Resistance · 2025 · Same journal
• Immunotherapy resistance and strategies in malignant pleural mesothelioma · Cancer Drug Resistance · 2026 · Same journal
• Effects of FAP+ cancer-associated fibroblasts on anti-PD-1 immunotherapy and CD4+ T cell polarization in gastric cancer · Cancer Drug Resistance · 2025 · Same journal
• TRAP1 ablation improves mitochondrial cristae and oxidative phosphorylation in pancreatic cancer stem cells · Cancer Drug Resistance · 2026 · Same journal
• Novel anti-tumor strategies: targeting the crosstalk between cancer stem cells and cancer-associated fibroblasts to resist drug resistance · Cancer Drug Resistance · 2026 · Same journal
• Unveiling the role of UGT enzymes in chemoresistance: a path to enhanced cancer pharmacotherapy · Cancer Drug Resistance · 2026 · Same journal
• Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an update · Cancer Drug Resistance · 2025 · Same journal
• Corosolic acid increases the therapeutic effect of cisplatin on gastric cancer by regulating Gpx4-dependent ferroptosis · Cancer Drug Resistance · 2025 · Same journal
• ROS1 mutations promote an immunosuppressive tumor microenvironment via MYC to confer immune evasion in head and neck cancer · Cancer Drug Resistance · 2025 · Same journal
• Roles and potential applications of non-coding RNAs in cancer treatment with immune checkpoint inhibitors and immunomodulatory therapies · Cancer Drug Resistance · 2026 · Same journal